ED
CORT icon

Exane Derivatives’s Corcept Therapeutics CORT Stock Holding History

Exane Derivatives’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-173
Closed -$2.06K – 699
2020
Q1 		$2.06K Hold
173
– – ﹤0.01% 500
2019
Q4 		$2.19K Sell
173
-4,780
-97% -$66.5K ﹤0.01% 491
2019
Q3 		$70K Hold
4,953
– – 0.01% 350
2019
Q2 		$55.2K Buy
+4,953
New +$55.2K 0.01% 384

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Exane Derivatives's CORT Position: Q2 2020 in Review

Exane Derivatives sold out of Corcept Therapeutics (CORT) in Q2 2020, closing a stake of 173 shares — an estimated $2.06K sold.

Exane Derivatives first reported a position in CORT in Q2 2019 and held it in 4 quarters. The position peaked at $70K in Q3 2019. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2020.

  • Exane Derivatives reported no remaining Corcept Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Exane Derivatives sold 173 Corcept Therapeutics shares in Q2 2020, an estimated $2.06K.
  • Exane Derivatives first reported a position in Corcept Therapeutics in Q2 2019 and held it in 4 quarters.
  • Exane Derivatives's Corcept Therapeutics position peaked at $70K in Q3 2019.
  • 224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2020.

Based on Exane Derivatives's 13F filing for Q2 2020, filed 10 Jul 2020.